Replies to post #409202 on Anavex Life Sciences Corp (AVXL)

[poguemahone]

Your post describes exactly how I feel as well. 8 years of loose ends, lack of transparency, and incomplete information. How is this acceptable to the BOD & shareholders? I have owned stock in numerous companies (and yes, several in other biotechs). AVXL is by far THE WORST at communicating to its stakeholders. Let’s not forget about the millions of CNS sufferers who also await better therapeutics. This company seems to be managed more like a country club, and not a leading edge biotechnology company on the cusp of innovative health science. If I seem angry ( and disillusioned), it is because I am. Where is the sense of urgency?!! You get the point.

It’s time for new leadership if we’re still saying this by June 30th, 2023. This will be the message that I’ll bring to the ASM, if they have it in person. My suspicion is that they’ll keep it remote to hide and avoid the angry mob that awaits them.

[Hoskuld]

There is always another question you can ask. What you wrote is true of every trial Biogen or Lilly or Pfizer etc has ever run.

[Investor2014]

Yes and the beef now would be for Anavex to correct that by comprehensively showing how they claim to have met all endpoints in the P2b/3 AD trial.

Not one time have they ever put out a completely comprehensive press release on trial data that left no loose ends.

Yesterday's PR did not help their cause and potentially opened up for accusations of having omitted information relating to the disappointing n of the PDD OLE trial. Not least because of their earlier claims of high rollover percentage of ELIGBLE patients into the OLE extension.

I think investors can now see how meaningless a high percentage of eligible patients can be with a the absolute n, not unlike Odds Ratios with no n and claims of having met all endpoints.